What Is TB-500? Definition and What Research Reports

Plain definition

TB-500 is a name commonly applied to a synthetic peptide marketed and discussed in research-chemical circles as a version of, or fragment derived from, thymosin beta 4 (abbreviated Tβ4 or TB4). Thymosin beta 4 is a small protein that occurs naturally in most human cells and in body fluids such as blood plasma and wound fluid. In the published scientific literature, almost all of the experimental work is reported under the name "thymosin beta 4," not "TB-500." The label TB-500 is therefore best understood as a market and community term that sits alongside — but is not identical to — a defined biological molecule studied in laboratories.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. Nothing here describes how any substance should be used.

What TB-500 is in biochemical terms

Thymosin beta 4 is a 43-amino-acid peptide belonging to the beta-thymosin family. Its best-characterised biochemical job is binding monomeric (G-) actin, which lets cells regulate how quickly actin filaments assemble and disassemble — the machinery behind cell shape change, crawling and migration. A review of the peptide's basic properties described Tβ4 as a multi-functional regenerative molecule with roles spanning cell migration, blood vessel formation, inflammation modulation and tissue repair, and summarised early clinical development programmes built around those properties (PMID 22074294).

Within Tβ4 there is a short internal sequence, often written as the actin-binding motif, that several research groups have investigated separately from the full-length protein. The TB-500 name is frequently attached to material described as this shorter active region. Because independent published characterisation of commercially labelled TB-500 is scarce, readers comparing a product name against the literature are effectively comparing a trade label to studies conducted on full-length thymosin beta 4.

Names and abbreviations readers encounter

Regulatory status

TB-500 is not an approved medicine in the United States, the European Union, the United Kingdom or Australia. Material sold under that name is typically offered as "research use only" (RUO), meaning it is not manufactured, tested or released to pharmaceutical standards for human administration. Thymosin beta 4 has appeared in investigational clinical programmes described in the review literature (PMID 22074294), but investigational status is not marketing approval. Several anti-doping frameworks also list TB-500 and related thymosin beta 4 preparations among prohibited substances in sport. This paragraph describes regulatory facts and is not legal advice.

How the term is used — and misused — in peptide research

• Used correctly: as shorthand for synthetic thymosin beta 4 material in a laboratory setting, with the understanding that published evidence is indexed under "thymosin beta 4."
• Misused: when preclinical Tβ4 findings in rodents, cell culture or engineered tissue are presented as if they were human outcomes for a purchased vial labelled TB-500.
• Misused: when TB-500 is confused with thymosin alpha 1, a structurally and functionally different thymic peptide.
• Misused: when the actin-binding fragment and full-length Tβ4 are treated as interchangeable despite being different molecules with different published datasets.
• Misused: when animal or in-vitro concentrations are reframed as human dosing information. No human dosing framework is established for TB-500.

What the published literature reports about thymosin beta 4

Cardiac and vascular models

Research reviewed in the cardiac repair literature reported that thymosin beta 4 promoted cardiomyocyte survival and vascular responses in experimental models of myocardial injury, with researchers describing effects on cell migration and capillary formation in animal hearts (PMID 20536454). In a separate laboratory system, the study applied Tβ4 to engineered heart tissues and reported improved differentiation and vascularisation of those constructs in culture (PMID 28191018). Both reports are preclinical; neither established clinical benefit in patients.

Fibrosis

A 2023 review examined what the authors called the "anti-fibrotic switch," summarising experimental work in which Tβ4 modulated fibrotic signalling and extracellular matrix deposition across several organ injury models (PMID 36580759). The review also noted context-dependence — that the peptide's effects on tissue remodelling were not uniformly protective across every model reviewed.

Kidney injury

Researchers reported that thymosin beta 4 alleviated sepsis-associated acute kidney injury in an experimental model, and attributed the effect to suppression of MAPK signalling (PMID 42417058). As with the cardiac work, this was laboratory research rather than a human trial.

Eye and infection models

A 2023 paper evaluated Tβ4 as a potential adjunct in bacterial keratitis, with the authors describing combined anti-inflammatory and wound-repair activity in corneal infection models (PMID 37018981). The paper framed the peptide as an adjunct candidate alongside antimicrobial therapy, not a replacement for it.

Neurological and neurodegeneration models

Several groups have studied Tβ4 in nervous-system models. One study reported that the peptide attenuated dysfunction in human brain endothelial cells exposed to the prion fragment PrP(106-126) (PMID 31877278), and a related report described protection of hippocampal neuronal cells against the same insult via neurotrophic factor signalling (PMID 37175330). In Alzheimer-relevant work, researchers reported that Tβ4 prevented systemic lipopolysaccharide-induced plaque load in middle-aged APP/PS1 mice (PMID 36878045), and a 2025 study using human brain organoids identified thymosin beta 4 as a candidate Alzheimer disease intervention target (PMID 40816274).

Hair follicle biology

A 2016 paper examined the role of thymosin beta 4 in hair growth, with the authors describing involvement of the peptide in follicle cell behaviour in experimental systems (PMID 27130465). This is frequently cited in community discussion of TB-500, though the published work concerns Tβ4 biology rather than any marketed product.

Safety Signals in the Literature: What Studies Report

The verified literature summarised here is overwhelmingly preclinical, and formal human safety datasets for TB-500 as a product do not exist in these papers. One line of research raises a biological caution worth noting: a 2025 mechanistic study reported that a Tβ4/SLC7A11 signalling pathway regulated breast cancer evolution, linking the peptide to tumour-relevant signalling in that experimental system (PMID 40912522). Separately, the anti-fibrotic review noted that tissue-remodelling effects were context-dependent rather than uniformly favourable (PMID 36580759). The broad regenerative review likewise described Tβ4 as multi-functional, which in pharmacological terms means its actions are not confined to a single tissue or pathway (PMID 22074294).

Related terms

• Actin sequestration — the binding of free actin monomers that underlies Tβ4's core biochemical function.
• Beta-thymosin family — the group of related small peptides to which Tβ4 belongs.
• Angiogenesis — new blood vessel formation, a recurring readout in cardiac and engineered-tissue studies (PMID 28191018).
• Research use only (RUO) — the labelling category under which TB-500 material is typically distributed.
• Preclinical — research in cells, tissues or animals, which describes nearly all Tβ4 evidence cited above.

How to read TB-500 claims

1. Check whether a claim cites thymosin beta 4 research or a product study — almost always the former.
2. Check the model: cell culture, rodent, engineered tissue or human.
3. Check whether the outcome was a mechanism (signalling change) or a clinical endpoint.
4. Treat single preclinical findings as hypothesis-generating, not as evidence of human effect.

References

• Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications (Expert Opinion on Biological Therapy, 2012)
• Thymosin beta4 and cardiac repair (Annals of the New York Academy of Sciences, 2010)
• Thymosin β4 Improves Differentiation and Vascularization of EHTs (Stem Cells International, 2017)
• Thymosin β4 and the anti-fibrotic switch (International Immunopharmacology, 2023)
• Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway (Clinical Science, 2026)
• Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis (International Immunopharmacology, 2023)
• Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction (European Journal of Pharmacology, 2020)
• Thymosin Beta 4 Protects Hippocampal Neuronal Cells against PrP(106-126) via Neurotrophic Factor Signaling (Molecules, 2023)
• Thymosin beta 4 prevents systemic lipopolysaccharide-induced plaque load in middle-age APP/PS1 mice (International Immunopharmacology, 2023)
• Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids (Stem Cell Reports, 2025)
• Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution (Cellular Signalling, 2025)
• Role of thymosin beta 4 in hair growth (Molecular Genetics and Genomics, 2016)